Gilead Sciences Inc (XTER:GIS)
€ 114.1 -0.76 (-0.66%) Market Cap: 143.26 Bil Enterprise Value: 155.94 Bil PE Ratio: 17.90 PB Ratio: 6.94 GF Score: 82/100

Gilead Sciences Inc at Bank of America Global Healthcare Conference Transcript

May 12, 2026 / 09:20PM GMT
Release Date Price: €115.66 (+1.55%)
Unidentified Participant

Guys. Welcome back to the Bank of America Healthcare Conference. Our next session is with Gilead Sciences. Sitting next to me on stage is Johanna Mercier, who is Chief Commercial Officer and Head of Corporate Affairs. Joanna, thank you for making the trip out west to see us today.

Johanna Mercier
Gilead Sciences Inc - Chief Commercial & Corporate Affairs Officer

Easy trip. Thank you. Thanks for having me.

Questions & Answers

Unidentified Participant

So for the few people who don't know, Gilead as well as some of the other people do, just give us a quick overview of the company and its focus areas and then we can go in some more detailed questions.

Johanna Mercier
Gilead Sciences Inc - Chief Commercial & Corporate Affairs Officer

Okay. Great. So Gilead Sciences is still a young company. It's just coming on to about 40 years or so. And that is specialized across three therapeutic areas. Some more developed than others, but HIV, oncology and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot